Ideas

Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) [MAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 3/February/2019, 10.39 pm
Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) [MAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 3/February/2019, 10.39 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors represent in vivo cancer…

read more

AIRE comes to the rescue of Diabetes Mellitus: AIRE (Autoimmune regulator) augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 2/February/2019, 6.11 pm
AIRE comes to the rescue of Diabetes Mellitus: AIRE (Autoimmune regulator) augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 2/February/2019, 6.11 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Molecular therapy for alleviating Diabetes: Alogliptin, an antidiabetic drug in the DPP-4 inhibitor class, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 2/February/2019, 5.54 pm
Molecular therapy for alleviating Diabetes: Alogliptin, an antidiabetic drug in the DPP-4 inhibitor class, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 2/February/2019, 5.54 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Molecular therapy for safeguarding your heart against cardiac dysfunction: Sofalcone, a gastrointestinal medication,  decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 2/February/2019, 5.44 pm
Molecular therapy for safeguarding your heart against cardiac dysfunction: Sofalcone, a gastrointestinal medication,  decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 2/February/2019, 5.44 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Alleviating Diabetes with amino acid Alanine: L-Alanine, a non-essential amino acid, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 2/February/2019, 1.27 pm
Alleviating Diabetes with amino acid Alanine: L-Alanine, a non-essential amino acid, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 2/February/2019, 1.27 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Molecular therapy for Diabetes Mellitus: CLOCK and BMAL1 augment the expression of FGF19 and FGF1,  attenuate hepatic glucose production, decrease hepatic acetyl CoA content, bring down the levels of plasma ACTH, and corticosterone, augment insulin sensitivity, promote weight loss and alleviate TIDM, via upregulation of its target gene, 31/January/2018, 11.51pm
Molecular therapy for Diabetes Mellitus: CLOCK and BMAL1 augment the expression of FGF19 and FGF1,  attenuate hepatic glucose production, decrease hepatic acetyl CoA content, bring down the levels of plasma ACTH, and corticosterone, augment insulin sensitivity, promote weight loss and alleviate TIDM, via upregulation of its target gene, 31/January/2018, 11.51pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more
Start Typing